生物活性

• 描述BMS-823778 is an orally available potent and selective inhibitor of 11-β-hydroxysteroid-dehydrogenase 1 (11βHSD-1). BMS-823778 is an antihyperglycaemic that may be a potential candidate for Type 2 diabetes treatment.
• 临床研究

• NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
  NCT01111955	Diabetes Mellitus, Type 2	Phase 2	Completed	-	United States, Florida ... more >> Farid Marquez, Md Hialeah, Florida, United States, 33012 United States, Washington Capital Clinical Reserch Center Olympia, Washington, United States, 98502 United States, Wisconsin Aurora Advanced Healthcare Milwaukee, Wisconsin, United States, 53209 Australia, New South Wales Local Institution Blacktown, New South Wales, Australia, 2148 Australia, Victoria Local Institution Box Hill, Victoria, Australia, 3128 Australia, Western Australia Local Institution Freemantle, Western Australia, Australia, 6959 Canada, British Columbia Local Institution Surrey, British Columbia, Canada, V4A 2H9 Canada, Manitoba Local Institution Winnipeg, Manitoba, Canada, R3E 3P4 Canada, New Brunswick Local Institution Bathurst, New Brunswick, Canada, E2A 4X7 Canada, Newfoundland and Labrador Local Institution St. John'S, Newfoundland and Labrador, Canada, A1A 3R5 Canada, Ontario Local Institution Thornhill, Ontario, Canada, L4J 8L7 Canada, Quebec Local Institution Mirabel, Quebec, Canada, J7J 2K8 Canada, Saskatchewan Local Institution Saskatoon, Saskatchewan, Canada, S7K 7H9 Canada Local Institution Quebec, Canada, G1N 4V3 Collapse <<
  NCT01602367	Hypertension	Phase 2	Terminated	-	-
  NCT01112423	Dyslipidemia	Phase 2	Completed	-	United States, Arkansas ... more >> Osborne Research Center Little Rock, Arkansas, United States, 72201 United States, Kansas Pra International Lenexa, Kansas, United States, 66219 United States, Ohio Sterling Research Grp, Ltd. Cincinnati, Ohio, United States, 45219 United States, Texas Cetero Research - San Antonio San Antonio, Texas, United States, 78229 United States, Virginia National Clinical Research - Norfolk, Inc. Norfolk, Virginia, United States, 23502 National Clinical Research - Richmond, Inc. Richmond, Virginia, United States, 23294 Australia, Queensland Local Institution Brisbane, Queensland, Australia, 4021 Canada, Manitoba Local Institution Winnipeg, Manitoba, Canada, R2V 4W3 Canada, Newfoundland and Labrador Local Institution Mount Pearl, Newfoundland and Labrador, Canada, A1N 1W7 Canada, Ontario Local Institution London, Ontario, Canada, N6A 5R8 Canada, Quebec Local Institution Drummondville, Quebec, Canada, J2B 7T1 Local Institution Montreal, Quebec, Canada, H3J 2V5 Collapse <<

• 更多
• 参考文献

• [1] Cheng Y, Wang L, et al. Clinical significance of CYP2C19 polymorphisms on the metabolism and pharmacokinetics of 11β-hydroxysteroid dehydrogenase type-1 inhibitor BMS-823778. Br J Clin Pharmacol. 2017 Aug 29.

  [2] Furlong MT, Ji QC, et al. A validated enantioselective LC-MS/MS assay for quantification of a major chiral metabolite of an achiral 11-β-hydroxysteroid-dehydrogenase 1 inhibitor in human plasma: Application to a clinical pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Jun 1;1022:167-172.